Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial

被引：0
|
作者：
Jun Guo
Jie Jin
Mototsugu Oya
Hirotsugu Uemura
Shunji Takahashi
Katsunori Tatsugami
Sun Young Rha
Jae-Lyun Lee
Jinsoo Chung
Ho Yeong Lim
Hsi Chin Wu
Yen Hwa Chang
Arun Azad
Ian D. Davis
Marlene J. Carrasco-Alfonso
Bhupinder Nanua
Jackie Han
Qasim Ahmad
Robert Motzer
机构：
[1] Peking University Cancer Hospital and Institute,Department Urology and Melanoma
[2] Peking University First Hospital,Department of Urology
[3] Keio University School of Medicine,Department of Urology
[4] Kindai University Faculty of Medicine,Department of Urology
[5] Cancer Institute Hospital,Department of Medical Oncology
[6] Japanese Foundation for Cancer Research,Department of Urology, Graduate School of Medical Sciences
[7] Kyushu University,Department of Oncology and Internal Medicine, Asan Medical Center
[8] Yonsei Cancer Center,Department of Urology
[9] Yonsei University College of Medicine,Division of Hematology
[10] University of Ulsan College of Medicine,Oncology
[11] Center for Prostate Cancer,Department of Urology
[12] National Cancer Center,Division of Urology, Department of Surgery
[13] Samsung Medical Center,Department of Medicine
[14] Sungkyunkwan University,Department of Medicine
[15] China Medical University Hospital,undefined
[16] Taipei Veterans General Hospital,undefined
[17] Monash University,undefined
[18] Monash University,undefined
[19] Eastern Health Clinical School,undefined
[20] Novartis Pharmaceuticals Corporation,undefined
[21] Novartis Pharmaceuticals Corporation,undefined
[22] Genitourinary Oncology Service,undefined
[23] Memorial Sloan-Kettering Cancer Center,undefined
来源：
Journal of Hematology & Oncology | / 11卷
关键词：
Renal cell carcinoma; Pazopanib; Sunitinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Renal safety of sunitinib treatment: A prospective study for patients (pts) with metastatic renal cell carcinoma (mRCC)
    Billemont, B.
    Rixe, O.
    Meric, J. B.
    Alexandre, J.
    Goldwasser, F.
    Izzedine, H.
    ANNALS OF ONCOLOGY, 2008, 19 : 36 - 36
  • [42] Efficacy and safety of ramucirumab (RAM) in Asian and non-Asian patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Subgroup analysis from two randomized studies
    Kang, Y-K.
    Kudo, M.
    Lim, H-Y.
    Hsu, C-H.
    Vogel, A.
    Brandi, G.
    Cheng, R.
    Carton, I.
    Abada, P.
    Hsu, Y.
    Zhu, A.
    Yen, C-J.
    ANNALS OF ONCOLOGY, 2018, 29 : 46 - 46
  • [43] Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma
    Molina, Ana M.
    Feldman, Darren R.
    Ginsberg, Michelle S.
    Kroog, Glenn
    Tickoo, Satish K.
    Jia, Xiaoyu
    Georges, Murielle
    Patil, Sujata
    Baum, Michael S.
    Reuter, Victor E.
    Motzer, Robert J.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (01) : 335 - 340
  • [44] Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma
    Ana M. Molina
    Darren R. Feldman
    Michelle S. Ginsberg
    Glenn Kroog
    Satish K. Tickoo
    Xiaoyu Jia
    Murielle Georges
    Sujata Patil
    Michael S. Baum
    Victor E. Reuter
    Robert J. Motzer
    Investigational New Drugs, 2012, 30 : 335 - 340
  • [45] A Phase II trial of dosage escalation of sorafenib in Asian patients with metastatic renal cell carcinoma
    Wang, Hong-kai
    Zhang, Hai-liang
    Zhu, Yao
    Yao, Xu-dong
    Zhang, Shi-lin
    Dai, Bo
    Shen, Yi-jun
    Zhu, Yi-ping
    Shi, Guo-hai
    Qin, Xiao-jian
    Ma, Chun-guang
    Lin, Guo-wen
    Xiao, Wen-jun
    Ye, Ding-wei
    FUTURE ONCOLOGY, 2014, 10 (12) : 1941 - 1951
  • [46] Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab plus Bevacizumab versus Sunitinib in Treatment-Naive Metastatic Renal Cell Carcinoma
    Atkins, Michael B.
    Rini, Brian I.
    Motzer, Robert J.
    Powles, Thomas
    McDermott, David F.
    Suarez, Cristina
    Bracarda, Sergio
    Stadler, Walter M.
    Donskov, Frede
    Gurney, Howard
    Oudard, Stephane
    Uemura, Motohide
    Lam, Elaine T.
    Ullich, Carsten Gr
    Quach, Caroleen
    Carroll, Susheela
    Ding, Beiying
    Zhu, Qian
    Piault-Louis, Elisabeth
    Schiff, Christina
    Escudier, Bernard
    CLINICAL CANCER RESEARCH, 2020, 26 (11) : 2506 - 2514
  • [47] A phase I/ II trial of pazopanib (Paz) alternating (alt) with bevacizumab (Bev) in treatment-naive metastatic clear cell renal cell carcinoma (mccRCC) patients (pts): Phase II results
    George, S.
    Vaishampayan, U. N.
    Hutson, A.
    Groman, A.
    Roche, C. L.
    Herbst, L.
    Kallicharsn-Smith, R.
    DiRaddo, A-M.
    Farrell, E.
    Kilari, D.
    Gopalakrishnan, D.
    Heath, E.
    Wulff-Burchfield, E.
    Appleman, L. J.
    Parikh, R.
    ANNALS OF ONCOLOGY, 2024, 35 : S1016 - S1017
  • [48] COST-MIMIMIZATION ANALYSIS OF PAZOPANIB VERSUS SUNITINIB, SORAFENIB AND BEVACIZUMAB plus INTERFERON a-2A FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
    Sura, M.
    Goryaynov, S.
    Avxentyeva, M.
    Omelyanovsky, V
    VALUE IN HEALTH, 2012, 15 (07) : A458 - A458
  • [49] Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma
    Xie, Mian
    He, Chaosheng
    Huang, Jinkun
    Lin, Qizhan
    Zou, Lixin
    ANNALS OF ONCOLOGY, 2015, 26 : 101 - 102
  • [50] Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma
    Xie, M.
    He, C.
    Huang, J.
    ANNALS OF ONCOLOGY, 2015, 26 : 71 - 71
12345